scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1110032962 |
P356 | DOI | 10.1186/S12885-018-5045-7 |
P932 | PMC publication ID | 6245867 |
P698 | PubMed publication ID | 30453910 |
P50 | author | Nikolas von Bubnoff | Q87841821 |
P2093 | author name string | Gabriele Ihorst | |
Jürgen Finke | |||
Justus Duyster | |||
Hartmut Bertz | |||
Olga Grishina | |||
Nadine Röthling | |||
Robert Zeiser | |||
P2860 | cites work | The pathophysiology of acute graft-versus-host disease. | Q53676885 |
Steroid-Refractory Acute GVHD: Lack of Long-Term Improved Survival Using New Generation Anticytokine Treatment | Q58814216 | ||
Graft-versus-host disease | Q83468020 | ||
Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease | Q87635679 | ||
Tyrosine kinase JAK1 is associated with the granulocyte-colony-stimulating factor receptor and both become tyrosine-phosphorylated after receptor activation | Q24563701 | ||
Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation | Q24626051 | ||
International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. | Q30994673 | ||
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis | Q33391880 | ||
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis | Q33399980 | ||
Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage. | Q34420372 | ||
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report | Q34474243 | ||
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey | Q36862931 | ||
New perspectives on the biology of acute GVHD. | Q37641063 | ||
When neutrophils meet T cells: beginnings of a tumultuous relationship with underappreciated potential. | Q38179308 | ||
Jak1 plays an essential role for receptor phosphorylation and Stat activation in response to granulocyte colony-stimulating factor | Q41099517 | ||
Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production | Q41908710 | ||
A high risk of life-threatening infectious complications in mycophenolate mofetil treatment for acute or chronic graft-versus-host disease | Q43136155 | ||
Advances in the clinical management of GVHD. | Q43170920 | ||
Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment | Q45164619 | ||
Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy | Q49679320 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | multicenter clinical trial | Q6934595 |
ruxolitinib | Q7383611 | ||
phase II clinical trial | Q42824440 | ||
P304 | page(s) | 1132 | |
P577 | publication date | 2018-11-19 | |
P1433 | published in | BMC Cancer | Q326300 |
P1476 | title | Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628) | |
P478 | volume | 18 |
Q92072381 | Emerging Topical and Systemic JAK Inhibitors in Dermatology |
Q96690572 | Impaired Virus-Specific T Cell Responses in Patients with Myeloproliferative Neoplasms Treated with Ruxolitinib |
Q92134267 | Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD |
Q92327065 | Ruxolitinib treatment for acute gastrointestinal graft-versus-host disease caused by donor-derived CD19-Chimeric antigen receptor T-Cell infusion in a patient with B-ALL relapsed after Allo-HSCT |
Q91522442 | Treatment and unmet needs in steroid-refractory acute graft-versus-host disease |
Search more.